OSCR Stock Recent News

Oscar's Q2 revenue rose 29% YoY to $2.86 billion, with membership growing 28% to over 2 million. The reported 91.1% MLR was distorted by a $692 million retroactive risk adjustment; normalized MLR was ~85.1%. SG&A dropped to 18.7% of revenue, driven by automation, AI, and vendor optimization, unlocking $60 million in annualized savings.

In this video, I will review Oscar's (OSCR 5.72%) earnings report and explain why I will be increasing my position. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Oscar Health, Inc. (NYSE:OSCR ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Chris Potochar - Vice President of Treasury & Investor Relations Mark Thomas Bertolini - CEO & Director Richard Scott Blackley - Chief Financial Officer Conference Call Participants Andrew Mok - Barclays Bank PLC, Research Division Craig Jones - BofA Securities, Research Division David Howard Windley - Jefferies LLC, Research Division Hua Ha - Robert W. Baird & Co. Incorporated, Research Division Jessica Elizabeth Tassan - Piper Sandler & Co., Research Division John Wilson Ransom - Raymond James & Associates, Inc., Research Division Jonathan Yong - UBS Securities LLC, Research Division Joshua Richard Raskin - Nephron Research LLC Stephen C.

Oscar Health (OSCR) Q2 Revenue Rises 29%

Oscar Health, Inc. (OSCR) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to earnings of $0.2 per share a year ago.

Oscar Health Wednesday reported a $228 million second quarter loss but sees profits returning next year as the health insurance industry navigates an influx of sicker-than-expected patients.

NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR) announced today its financial results for the second quarter ended June 30, 2025, and reaffirmed its updated full year 2025 outlook across all metrics as provided in its preliminary financial results press release dated July 22, 2025. “We believe the individual market has long-term upside and is the future of healthcare,” said Mark Bertolini, CEO of Oscar Health. “Oscar is well-positioned to manage through the.

Oscar Health is facing short-term ACA market concerns and negative analyst sentiment. I think it will be short-lived. The company is expanding into the high-potential ICHRA market, leveraging operational scale and AI-driven care coordination to improve margins. Current market concerns are cyclical, not structural. Valuation suggests growth rate is overlooked and company is mispriced.

Oscar Health's online, individual-focus model has reached scale, but profitability now faces headwinds from higher medical loss ratios and policy uncertainty. Recent guidance revision signals increased risk and a potential operating loss for 2025, despite higher projected revenue and strong Q1 results. The balance sheet remains healthy, but short-term growth is likely delayed as Oscar adapts to new industry data and rising costs.

The latest trading day saw Oscar Health, Inc. (OSCR) settling at $13.58, representing a -3.35% change from its previous close.